Gri bio (nasdaq: gri) announces board of director appointments adding leadership and expertise spanning a combined 75 years in both public and private sectors in the life sciences industry

La jolla, ca, april 24, 2023 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (“nkt”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointments of david szekeres, roelof rongen, mse, mba, and camilla v. simpson, m.sc. to the company's board of directors. mr. szekeres will serve as chairman of the board. as previously announced, gri bio will commence trading on the nasdaq capital market under the ticker symbol “gri”, effective today, april 24, 2023, as a result of its recently completed its merger with vallon pharmaceuticals, inc.
GRI Ratings Summary
GRI Quant Ranking